SD3212, a new antiarrhythmic drug, raises atrial fibrillation threshold in isolated rabbit hearts

Heart and Vessels

Volumn 14, Issue 3, 1999, Pages 127-136

  Matsuo, Ryohei ^a   Shirayama, Takeshi ^a   Inoue, Keiji ^a   Matoba, Yayoi ^a   Imai, Hiroto ^a   Shiraishi, Hirokazu ^a   Tatsumi, Tetsuya ^a   Nakagawa, Masao ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Electrophysiology; SD3212

Indexed keywords

ACETYLCHOLINE; SESAMODIL FUMARATE;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0033459520     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02482296     Document Type: Article

References (31)

1. Natale A, Blanck Z, Deshpande S, Dhala A, Jazayeri M, Sra J, Akhtar M (1995) Current concerns and future directions in the pharmacological treatment of atrial fibrillation. In: DiMarco JP, Prystowsky EN (eds) Atrial arrhythmias. State of the art. Futura, New York, pp 387-401
2. Gilligan DM, Ellenbogen KA, Epstein AE (1996) The management of atrial fibrillation. Am J Med 101:413-421
3. Ganz LI, Antman EM (1997) Antiarrhythmic drug therapy in the management of atrial fibrillation. J Cardiovasc Electrophysiol 8:1175-1189
4. Singh BN (1996) Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 78(4A):41-53
5. Maisel WH, Kuntz KM, Reimold SC, Lee TH, Antman EM, Friedman PL, Stevenson WG (1997) Risk of initiating antiarrhythmic drug therapy for atrial fibrillation patients admitted to a university hospital. Ann Intern Med 127:281-284
6. Grey E, Silverman DI (1993) Efficacy of type IC antiarrhythmic agents for treatment of resistant atrial fibrillation. PACE 16:2235-2240
7. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, Goldberg H, Scheinman MM (1989) Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13:442-449
8. Echt DS, Liebson PR, Mitchell LB, Peters RN, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DN, CAST investigators (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788
9. Kodama I, Suzuki R, Maruyama K, Toyama J (1995) Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guinea-pig ventricular cells. Br J Pharmacol 114:503-509
10. Takahashi N, Ito M, Ishida S, Fujino T, Maruyama T, Saikawa T (1995) Electrophysiological effects of SD-3212, a novel antiarrhythmic agent, on rabbit hearts in vivo and in vitro. J Cardiovasc Pharmacol 25:1006-1011
11. Hondeghem LM, Snyders DJ (1990) Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and danger of reverse use-dependence. Circulation 81:686-690
12. Hara Y, Nakaya H (1995) SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine receptor-operated potassium current in guinea-pig atrial cells. Br J Pharmacol 116:2750-2756
13. ++ channel blocker, in anaesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3212) and bepridil. Naunyn-Schmiedeberg's Arch Pharmacol 345:688-695
14. Nakayama K, Morimoto K, Nozawa Y, Tanaka Y (1992) Calcium antagonistic and binding properties of semotiadil (SD-3211), a benzothiazepine derivative assessed in cerebral and coronary arteries. J Cardiovasc Pharmacol 20:380-391
15. Fukuchi M, Uematsu T, Nagashima S, Nakashima M (1990) Antiarrhythmic effects of a benzothiazepine derivative (SD-3211) and its stereoisomer (SD-3212) in anaesthetized rats and islated perfused rat hearts compared with bepridil. Naunyn-Schmiedeberg's Arch Pharmacol 341:557-564
16. 2+ channel blocker SD-3212: a comparison with its enantiomer (SD-3211). Drug Dev Res 22:293-298
17. Hirasawa A, Haruno A, Matsuzaki T, Hashimoto K (1992) Effects of new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Jpn Heart J 33:851-861
18. Allessie MA, Lammers WJEP, Bonke IM, Hollen J (1984) Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 70:123-135
19. Euler DE, Scanlon PJ (1987) Acetylcholine release by a stimulus train lowers atrial fibrillation threshold. Am J Physiol 253:H863-H868
20. Inoue M, Inoue D, Ishibashi K, Sakai R, Omori I, Yamahara Y, Asayama J, Nakagawa M (1993) Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. Jpn Heart J 34:301-312
21. Ravelli F, Allessie MA (1997) Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96:1686-1695
22. Ishibashi K, Inoue D, Sakai R, Inoue M, Shirayama T, Asayama J, Nakagawa M (1995) Effects of disopyramide on the atrial fibrillation threshold in the human atrium. Int J Cardiol 52:177-184
23. Wijffel MCE, Kirchhof CJHJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954-1968
24. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ (1988) Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 62:395-410
25. Toda I, Murakami Y, Nozaki A, Kawakubo K, Sugimoto T (1988) Ventricular fibrillation threshold measured by continuous 50cps stimulation for the evaluation of the antifibrillatory effect of the drugs. Jap Cire J 52:249-253
26. Sugimoto T, Schaal SF, Wallace AG (1967) Factors determining vulnerability to ventricular fibrillation induced by 60-cps alternating current. Circ Res 11:601-608
27. Coumel P (1992) Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ (eds) Atrial fibrillation: mechanisms and management. Raven, New York, pp 109-125
28. Janse MJ (1989) Anisotropic conduction in the atrium: its role in arrhythmogenesis. In: Attuel P, Coumel P (eds) The atrium in health and disease. Futura, New York, pp 15-26
29. Schuessler RB, Boineau JP, Bromberg BI, Hand DE, Yamauchi S, Cox JL (1995) Normal and abnormal activation of the atrium. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology from cell to bedside. Saunders, Philadelphia, pp 543-562
30. Spach MS (1995) Nonuniform anisotropic cellular coupling as a basis for reentrant arrhythmias. In: DiMarco JP, Prystowsky EN (eds) Atrial arrhythmias. State of the art. Futura, New York, pp 123-147
31. Papageorgiou P, Monahan K, Boyle NG, Seifert MJ, Beswick P, Zebede J, Epstein LM, Josephson ME (1996) Site-dependent intra-atrial conduction delay. Relationship to initiation of atrial fibrillation. Circulation 94:384-389